Transcatheter annuloplasty ring for mitral regurgitation

Series
Mitral valve procedures
Status
Published
Date
Number of report
006

Ask the expert

(we accept only company emails)

Report presents summary of the reimbursement situation for a transcatheter annuloplasty ring for mitral regurgitation. The method is transcatheter alternative of open surgery placement of annuloplasty ring.

    Report includes essential information about reimbursement and national funding of the transcatheter annuloplasty ring for mitral regurgitation, including:

    • Brief overview of reimbursement system for medical devices
    • Procedure coding for technology
    • Diagnosis coding
    • Payment mechanism for technology
    • Reimbursement tariffs for technology
    • Restrictions in indications or scenarios for use of technology
    • Policy considerations by payers and policy-makers about technology

    Reimbursement information is provided for the following geographies:

    • Austria
    • Belgium
    • Denmark
    • England (UK)
    • France
    • Germany
    • Italy
    • Netherlands
    • Norway
    • Sweden
    • Switzerland

    Manufacturers and developers of the technology include:

    • Edwards Lifesciences (CardioBand)

    Table of content

    1.    Introduction and summary
    2.    Executive summary table
    3.    Contents
    4.    Methodology
    5.    Reimbursement analysis in Austria

    5.1.    Overview of the reimbursement system
    5.2.    Reimbursement for transcatheter annuloplasty ring
    6.    Reimbursement analysis in Belgium
    6.1.    Overview of the reimbursement system
    6.2.    Reimbursement for transcatheter annuloplasty ring
    7.    Reimbursement analysis in Denmark
    7.1.    Overview of the reimbursement system
    7.2.    Reimbursement for transcatheter annuloplasty ring
    7.2.1.    Procedure coding 
    7.2.2.    Diagnosis coding
    7.2.3.    Payment mechanism and reimbursement tariffs
    8.    Reimbursement analysis in England
    8.1.    Overview of the reimbursement system
    8.2.    Reimbursement for transcatheter annuloplasty ring
    8.2.1.    Procedure coding 
    8.2.2.    Diagnosis coding
    8.2.3.    Payment mechanism and reimbursement tariffs
    8.2.4.    Policy considerations 
    8.2.4.1.    National commissioning by NHS England
    9.    Reimbursement analysis in France
    9.1.    Overview of the reimbursement system
    9.2.    Reimbursement for transcatheter annuloplasty ring
    10.    Reimbursement analysis in Germany
    10.1.    Overview of the reimbursement system
    10.2.    Reimbursement for transcatheter annuloplasty ring
    10.2.1.    Procedure coding 
    10.2.2.    Diagnosis coding
    10.2.3.    Payment mechanism and reimbursement tariffs
    10.2.4.    Policy considerations
    11.    Reimbursement analysis in Italy
    11.1.    Overview of the reimbursement system
    11.2.    Reimbursement for transcatheter annuloplasty ring
    11.2.1.    Procedure coding at national level
    11.2.2.    Diagnosis coding
    11.2.3.    Payment mechanism and reimbursement tariffs at national level
    11.2.4.    Payment mechanism and reimbursement tariffs at regional level
    12.    Reimbursement analysis in the Netherlands
    12.1.    Overview of the reimbursement system
    12.2.    Reimbursement for transcatheter annuloplasty ring
    13.    Reimbursement analysis in Norway
    13.1.    Overview of the reimbursement system
    13.2.    Reimbursement for transcatheter annuloplasty ring
    13.2.1.    Procedure coding 
    13.2.2.    Diagnosis coding
    13.2.3.    Payment mechanism and reimbursement tariffs
    14.    Reimbursement analysis in Sweden
    14.1.    Overview of the reimbursement system
    14.2.    Reimbursement for transcatheter annuloplasty ring
    14.2.1.    Procedure coding 
    14.2.2.    Diagnosis coding
    14.2.3.    Payment mechanism and reimbursement tariffs
    15.    Reimbursement analysis in Switzerland
    15.1.    Overview of the reimbursement system
    15.2.    Reimbursement for transcatheter annuloplasty ring
    15.2.1.    Procedure coding 
    15.2.2.    Diagnosis coding
    15.2.3.    Payment mechanism and reimbursement tariffs
    15.2.4.    Policy considerations 
    15.2.4.1.    Restrictions for percutaneous interventional treatment of severe mitral valve insufficiency in the Health Benefit List
    16.    Disclaimer
     

    11

    Jun 2018

    On 11th May, the Italian Ministry of Health announced from its website that five new Med Tech-related HTA documents are available for public consultation. See the details in the MTRC post.

    Read more

    20

    Nov 2017

    Annual report from the Italian Society of Interventional Cardiology (GISE) shows increasing trends in procedural volume of percutaneous coronary interventions (PCI), transcatheter aortic valve implantations (TAVI), mitral clip implantations, closure of left atrial appendage (LAA) and patent foramen ovale (PFO).

    Read more

    04

    May 2017

    Check out reimbursement summary for the most established transcatheter mitral valve repair procedure in England, France and Germany. Reimbursement is established in Germany and France (for one indication). It is in process to be established in England and in France (for other indications).

    Read more

    25

    Apr 2017

    The procedure can be coded in Austria, Denmark, England, Germany, Italy, Netherlands, Norway, Sweden and Switzerland, so payment mechanism is in place, even with an inadequate tariff in some countries. In countries where the procedure is not coded, it cannot be reimbursed. Despite available reimbursement mechanism, funding has not been established yet in majority of geographies.

    Read more

    10

    Apr 2017

    Reports presents summary of the reimbursement situation in Europe for all developed or currently under development minimally invasive (transapical approach via mini-thoracotomy) and transcatheter mitral valve repair and replacement procedures for mitral regurgitation.

    Read more

    15

    Mar 2017

    MTRC is working on release of 9 reimbursement reports for medical technologies during March 2017, including report for transcatheter aortic valve replacement and eight minimally invasive mitral valve repair and replacement procedures.

    Read more
    (we accept only company emails)